Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Allergic Asthma
Phase PHASE2
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter, randomized, masked, active and placebo controlled, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetics of LP-003 injection in adult patients with moderate to severe persistent allergic asthma.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Biological: LP-003 Injection — s.c. injection, Q12W
  • Biological: Omalizumab — s.c. injection, Q4W
  • Biological: Placebo — s.c. injection, Q4W

Primary Outcomes

  • Mean number of asthma exacerbations per subject (During the 24-week treatment period)
  • Proportion of subjects with asthma exacerbations (During the 24-week treatment period)
  • Mean number of asthma exacerbations per subject (During the 36-week and 48-week follow-up period)
  • Proportion of subjects with asthma exacerbations (During the 36-week and 48-week follow-up period)
  • Proportion of subjects with loss of asthma control (LOAC) in each group (During the 24-week treatment period)
  • Incidence of adverse events (AEs) (Up to approximately 52 weeks)
  • Change from baseline in pre-bronchodilator FEV1, FVC, and FEV1/FVC ratio (Weeks 4, 8, 12, 16, 20, and 24)
  • Change from baseline in weekly mean daily and weekly Peak Expiratory Flow (PEF) variability, and change from baseline in mean PEF (Weeks 4, 8, 12, 16, 20, and 24)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-01-25
Completion: 2029-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Longbio Pharma
Principal Investigators:
  • Jieming Qu (PRINCIPAL_INVESTIGATOR) - Ruijin Hospital
Contact Information
Study Contact:
Jie Yang
+86 021-58372390
yangj@longbiopharma.com
Wei Tang
+86 189170 0579
tina_tangwei@163.com
Ruijin Hospital
Interventions
  • Biological: LP-003 Injection — s.c. injection, Q12W
  • Biological: Omalizumab — s.c. injection, Q4W
  • Biological: Placebo — s.c. injection, Q4W
Study Locations (1 sites)
Ruijin Hospital, Shanghai, China
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years and ≤ 75 years, no gender restriction; 2. Body weight ≥ 40 kg; 3. Diagnosed with bronchial asthma for at least 1 year according to the "Guidelines for Prevention and Treatment of Bronchial Asthma (2020 Edition)", and diagnosed with allergic asthma according to the "Chinese Guidelines for the Diagnosis and Treatment of Allergic Asthma (2019 Edition)" ; At least 1 asthma exacerbation in the year prior to screening (referring to GINA and Chinese guidelines, asthma exacerbation is defined as worsening of asthma symptoms requiring systemic glucocorticoid treatment for at least 3 days, and/or multiplying the dose of inhaled glucocorticoids for at least 3 days); 4. Positive bronchial dilation test within 24 months prior to screening or at the time of screening; 5. Subjects with at least one positive skin prick test or positive serum specific IgE test result for a relevant allergen within 12 months prior to randomization; 6. Subjects who have received medium to high dose inhaled corticosteroids (ICS) treatment for at least 8 weeks prior to screening (fluticasone propionate \>250 μg/day or equivalent dose of ICS, not exceeding fluticasone propionate 2000 μg/day or equivalent dose of ICS, as per the "Guidelines for Prevention and Treatment of Bronchial Asthma (2020 Edition)"), have maintained stable use for 4 weeks before randomization, with asthma remaining partially controlled or uncontrolled (defined as ACT score ≤ 19); 7. Combined with at least one other asthma control medication (long-acting β2 receptor agonists (LABA), long-acting muscarinic antagonists (LAMA), leukotriene receptor antagonists (LTRA), and sustained-release theophylline treatment) and stable use for 4 weeks before randomization ; 8. At screening, 40% \< FEV1 \< 80% of predicted value; 9. Subjects who have no plans for pregnancy and agree to take effective contraceptive measures during the trial and for 6 months after the last dose of study treatment; 10. Subjects who voluntarily sign the ICF, are able to understand and correctly fill out the assessment form, correctly use the PEF device and record the patient diary card, and attend follow-up visits as scheduled.Male or female, aged 18 to 75 years. Exclusion Criteria: 1. Allergic to the investigational product and its excipients or Xolair® ; 2. Coexisting diseases other than asthma that may affect lung function, such as chronic obstructive pulmonary disease (COPD), allergic bronchopulmonary aspergillosis (ABPA), and bronchiectasis, which, in the investigator's judgment, may place the subject at inappropriate risk or affect the assessment of study results; 3. Patients who have severe or uncontrolled diseases of the liver, kidneys, gastrointestinal tract, cardiovascular and cerebrovascular systems, hematopoietic system, urogenital system, endocrine system, nervous system, immune system, etc.; 4. Clinically significant infection history within 4 weeks prior to randomization, as assessed by the investigator, affecting patient evaluation; 5. Major surgery within 4 weeks prior to randomization or planned surgical procedures during the study period, or treatments that the investigator believes may affect patient evaluation; 6. Known parasitic infection within 6 months prior to randomization; 7. History of malignancy diagnosed within 5 years prior to screening; 8. Clinically significant abnormalities in laboratory tests during the screening period and baseline, deemed unsuitable for participation by the investigator ; 9. Positive test for human immunodeficiency virus (HIV) antibodies at screening, or positive for treponema pallidum antibodies (except RPR or TRUST negative), or positive for hepatitis B surface antigen (except HBV-DNA below the detection limit of the site), or positive for hepatitis B core antibody (except HBV-DNA below the detection limit of the site), or positive for hepatitis C virus (HCV) antibodies (except HCV RNA below the detection limit of the site); 10. Still smoking or having quit smoking for less than 6 months at screening, or a history of smoking ≥10 pack-years \[Smoking Index (pack-years) = daily smoking amount (packs) × smoking duration (years), 1 pack = 20 cigarettes\]; 11. Used biological agents such as monoclonal antibodies, including investigational biological agents, within 3 months prior to screening or within 5 half-lives of the drug (whichever is longer); 12. Received systemic immunosuppressants or systemic glucocorticoids (dose equivalent to prednisone \>10 mg/day) for inflammatory or autoimmune diseases (such as rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, etc.) within 8 weeks prior to screening or within 5 half-lives of the drug (whichever is longer); 13. Specific allergen immunotherapy conducted within 3 months prior to screening; 14. Live (attenuated) virus/bacterial vaccines administered or intravenous immunoglobulin used within 4 weeks prior to screening; 15. Participation in other drug clinical trials within 3 months or 5 half-lives of the drug (whichever is longer) prior to screening; 16. History of drug abuse, substance abuse, and/or excessive alcohol consumption within 1 year prior to screening; 17. Pregnant or breastfeeding women; 18. Any other condition that makes the subject unsuitable for participation in the trial as assessed by the investigator.
Conditions Pulmonary Arterial Hypertension
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if an exercise programme started shortly after diagnosis improves the fitness and mental wellbeing of patients with pulmonary hypertenion over and above medication alone. It will also learn about whether extra support can help patients keep up with exercise in the long term. The main questions it aims to answer are: * Doe exercise improve how far patients can walk over six minutes * Does exercise improve quality of life scores * Does exercise improve mental health scores * Does extra support after an exercise programme help patients to continue exercising in the long term Researchers will compare the exercise programme to a control group (a group of similar patients who do not receive the exercise programme) to see the effect that exercise has. Participants in the exercise programme group will: * Undergo an exercise programme for 12 weeks, starting around 3 months after their diagnosis * They will undertake the exercise programme at home, remotely supervised by the research team with regular contact * Visit the clinic at the end of the programme for checkups and tests * Keep a diary of their exercise and how they are feeling Participants in the control group will: -Still undergo the exercise programme, but this will happen at a delayed time, starting around 6 months after diagnosis, to allow for a comparison between the two groups. Following completion of the exerise programme: * Half of participants will receive extra support to help them continue to exercise * The other half will not receive any additional support * All patients will be reviewed 1 year following the completion of their exercise programme to monitor their ongoing exercise levels.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Home-based, remotely delivered, supervised Exercise programme — A home-based remotely delivered supervised exercise programme

Primary Outcomes

  • Six-minute walk distance (Around 6 months post diagnosis. (After completion of the exercise programme for those in the intervention group, and on medical therapy alone for those in the control group).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-02
Completion: 2028-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Golden Jubilee National Hospital
Collaborators: Chiesi Farmaceutici S.p.A., University of Glasgow
Contact Information
Study Contact:
Jamie Ingram, MBChB
0044 141-951-5440
jamie.ingram2@nhs.scot
Colin Church, BSc, MBChB, PhD, FRCP
0044 141-951-5497
colinchurch@doctors.org.uk
Jamie Ingram, MBChB
00441419515497
jamie.ingram2@nhs.scot
Golden Jubilee National Hospital
Interventions
  • Other: Home-based, remotely delivered, supervised Exercise programme — A home-based remotely delivered supervised exercise programme
Study Locations (1 sites)
Golden Jubilee National Hospital, Glasgow, G814DY United Kingdom
Eligibility Criteria
Inclusion Criteria: * Aged 18-years-old and above * Diagnosed with pulmonary hypertension (group I and non-operable group IV) by right heart catheterisation showing: * a baseline mean pulmonary artery pressure \>20mmHg * pulmonary vascular resistance \>2 Wood Units * pulmonary capillary wedge pressure \<15mmHg * Able to provide written informed consent Exclusion Criteria: * Diagnosis with pulmonary hypertension of any other cause * Group II (PH due to left heart disease) * Group III (PH due to hypoxic lung disease) * Operable group IV (PH due to chronic thromboembolic disease amenable to surgical treatment) * Group V (unclear and/or multifactorial elements). * Planned treatment with a research trial medication during the study timeframe * Consenting clinician and/or patient concern regarding the patient's safety in performing a home-based exercise programme * Patients with syncopal episodes felt to be related to pulmonary hypertension at time of exercise intervention initiation. * Severe concurrent medical condition that would prevent participation in study procedures * Life expectancy \<3 months
Conditions HER2 + Breast Cancer
Phase PHASE2, PHASE3
Enrollment 706
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study is being conducted to evaluate the clinical efficacy of HLX22 in combination with HLX87 as first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer

Design

Study type: Interventional Phases: Phase2, Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: HLX87 + HLX22 — HLX87 is a novel HER2-targeted ADC with a similar mechanism of action to trastuzumab deruxtecan. HLX22 is a novel monoclonal antibody targeting HER2 .
  • Drug: HLX87 + Pertuzumab — HLX87 is a novel HER2-targeted ADC with a similar mechanism of action to trastuzumab deruxtecan
  • Drug: T-Dxd + Pertuzumab — T-Dxd is a HER2-targeted ADC
  • Drug: THP — Pertuzumab+ Trastuzumab+Docetaxel

Primary Outcomes

  • Objective response rate (ORR) (assessed by the blinded independent central review [BICR] as per RECIST v1.1) (up to 26 months)
  • Progression-free survival (PFS) (assessed by BICR as per RECIST v1.1) (up to 37 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Status: Recruiting
Start Date: 2026-02-27
Completion: 2030-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 706 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Henlius Biotech
Principal Investigators:
  • Fei Ma, Dr (PRINCIPAL_INVESTIGATOR) - Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Contact Information
Study Contact:
Maoqing Fu, Dr
021-33395800
Maoqing_fu@henlius.com
Ma
01067781331
Mafei@163.com
Fei Ma, Dr
86-010-87788888
Feima2011@169.com
Cancer Hospital, Chinese Academy of Medical Sciences
Interventions
  • Drug: HLX87 + HLX22 — HLX87 is a novel HER2-targeted ADC with a similar mechanism of action to trastuzumab deruxtecan. HLX22 is a novel monoclonal antibody targeting HER2 .
  • Drug: HLX87 + Pertuzumab — HLX87 is a novel HER2-targeted ADC with a similar mechanism of action to trastuzumab deruxtecan
  • Drug: T-Dxd + Pertuzumab — T-Dxd is a HER2-targeted ADC
  • Drug: THP — Pertuzumab+ Trastuzumab+Docetaxel
Study Locations (1 sites)
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality 100021 China
Eligibility Criteria
Inclusion Criteria: * 1\. Have a full understanding of the study content, and sign the informed consent form (ICF); 2. Aged ≥ 18 years at the time of signing the ICF, male or female; 3. Histopathologically confirmed breast cancer that meets the following criteria: 1. Advanced or metastatic breast cancer. 2. HER2-positive as determined by the central laboratory, defined as IHC 3+, or IHC 2+ and ISH+. 3. Positive or negative for hormone receptor HR (including estrogen receptor \[ER\] and progesterone receptor \[PgR\]) as determined by the central laboratory 4. No prior chemotherapy or HER2-targeted therapy for advanced or metastatic breast cancer (1 line of endocrine therapy is allowed). 5\. At least one measurable lesion as assessed by central imaging according to RECIST v1.1. 7\. Eastern Cooperative Oncology Group performance status score within 7 days prior to the first dose of study drugs: 0-1. 8\. Life expectancy ≥ 12 weeks. 9. Adequate organ functions Exclusion Criteria: * 1\. History of a second malignancy within 3 years prior to signing the ICF. 2. Previous use of doxorubicin with a concentration of \> 360 mg/m2 (or equivalent). 3\. Prior treatment with ADCs including exatecan derivatives that contain topoisomerase I inhibitors. 4\. Uncontrolled or significant cardiovascular diseases 5. Cerebrovascular accidents within 6 months prior to the first dose of study drugs. 6\. ILD/pneumonitis, or suspected ILD/pneumonitis or clinically significant lung-specific intercurrent illness . 7\. Active infection . 8. Presence of spinal cord compression or clinically symptomatic central nervous system metastases. 9\. Residual toxicity from previous anti-tumor therapy that has not resolved to Grade ≤ 1 as per NCI-CTCAE V6.0 or baseline level (except for alopecia). 10\. Presence of active tuberculosis. 11. Have received treatment with live attenuated vaccines within 30 days prior to the first dose of study drugs. 12\. Known history of severe allergic reaction to macromolecular protein preparations, hypersensitivity to the ingredient of the investigational products, or severe hypersensitivity to any excipient of the study drugs. 13\. Known history of abuse of psychotropic drugs or drug addiction. 14. Pregnant or lactating women.
Conditions Breast Cancer
Phase PHASE2
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is a randomized, open-label, multicenter clinical study for patients with early or locally advanced (T≥2cm, N0-3, M0) HER2-positive breast cancer, aiming to compare the peripheral blood ctDNA clearance of neoadjuvant pyrotinib + trastuzumab + docetaxel and pertuzumab + trastuzumab + docetaxel for one course and to evaluate the therapeutic effectiveness of four courses of neoadjuvant therapy

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: pyrotinib — pyrotinib 320mg p.o. qd
  • Drug: pertuzumab — pertuzumab ivgtt q3w, 840mg for initiation, 420mg for maintenance
  • Drug: trastuzumab — trastuzumab ivgtt q3w, 8mg/kg for initiation, 6mg/kg for maintenance
  • Drug: docetaxel — docetaxel ivgtt q3w, 80-100mg/m2

Primary Outcomes

  • ctDNA clearance after one cycle neoadjuvant treatment (3 months after neoadjuvant treatment initation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-02-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Jiao Tong University School of Medicine
Contact Information
Study Contact:
Haoyu Wang
86 18817865256
meredithwhy@163.com
Haoyu Wang
86 18817865256
meredithwhy@163.com
Ruijin Hospital
Interventions
  • Drug: pyrotinib — pyrotinib 320mg p.o. qd
  • Drug: pertuzumab — pertuzumab ivgtt q3w, 840mg for initiation, 420mg for maintenance
  • Drug: trastuzumab — trastuzumab ivgtt q3w, 8mg/kg for initiation, 6mg/kg for maintenance
  • Drug: docetaxel — docetaxel ivgtt q3w, 80-100mg/m2
Study Locations (1 sites)
Ruijin Hospital, Shanghai, 200025 China
Eligibility Criteria
Inclusion Criteria: * histologically diagnosed with Stage II-III HER2+ breast cancer (primary diameter \>2cm) * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 * Intact renal, hepatic, bone marrow and cardiac functions including baseline left ventricular ejection fraction (LVEF) ≥ 55% measured by echocardiography * No prior treatment Exclusion Criteria: * Bilateral or metastatic breast cancer * History of other malignancies * Severe cardiovascular disease * Allergic to any of the regimens
Conditions Gynecologic Cancer, Urologic Cancer, Bre...
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Cancer treatment is multidisciplinary and may include radiotherapy. Treatment-related complications represent a burden for patients and the healthcare system. Early recognition of radiotherapy-related side effects is important for timely clinical interventions and improved quality of care. This study aims to improve comprehensive patient management during and after radiotherapy through development and implementation of a web-based application using standardized electronic patient-reported outcome questionnaires (PROMs). Patients will report radiotherapy-related symptoms and quality of life through web-based questionnaires that will be securely transmitted to the Institute of Oncology Ljubljana for review by healthcare professionals. Responses will be categorized using a traffic-light system to guide clinical actions and optimize follow-up visits.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Web-Based Application for PROM Monitoring During Radiotherapy — Participants use a web-based application to complete standardized electronic PROM questionnaires on radiotherapy-related side effects and quality of life. Data are securely transmitted to the Institute of Oncology Ljubljana, reviewed by healthcare professionals, and used for clinical triage and optimization of follow-up visits.

Primary Outcomes

  • Prediction of Radiotherapy-Related Adverse Effects Using Electronic Patient-Reported Outcome Measures (PROMs) (From baseline (start of radiotherapy) through 2 years after completion of radiotherapy.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-02
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institute of Oncology Ljubljana
Contact Information
Study Contact:
Barbara Zobec Logar, MD
+38615879273
HLogar@onko-i.si
Klavdija Korošec
kkorosec@onko-i.si
Klavdija Korošec
+386 31630065
kkorosec@onko-i.si
Institute of Oncology Ljubljana
Interventions
  • Other: Web-Based Application for PROM Monitoring During Radiotherapy — Participants use a web-based application to complete standardized electronic PROM questionnaires on radiotherapy-related side effects and quality of life. Data are securely transmitted to the Institute of Oncology Ljubljana, reviewed by healthcare professionals, and used for clinical triage and optimization of follow-up visits.
Study Locations (1 sites)
Institute of Oncology Ljubljana, Ljubljana, 1000 Slovenia
Eligibility Criteria
Inclusion Criteria: * Patients receiving radiotherapy for gynecologic cancer, urologic cancer, or breast cancer at the Institute of Oncology Ljubljana. * Ability to access and use the web-based application on a smartphone, computer, or tablet. * Signed written informed consent. Exclusion Criteria: * Inability to understand the questionnaire questions and provide meaningful answers.
Conditions Breast Cancer
Phase PHASE2
Enrollment 80
Locations 58 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A study to evaluate the efficacy and safety of triplet combination of inavolisib plus ribociclib and fulvestrant versus placebo plus ribociclib and fulvestrant in the first-line setting in participants with endocrine-therapy-resistant hormone receptor (HR)-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC).

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Inavolisib — Inavolisib will be administered as per the schedule mentioned in the protocol.
  • Drug: Ribociclib — Ribociclib will be administered as per the schedule mentioned in the protocol.
  • Drug: Fulvestrant — Fulvestrant will be administered as per the schedule mentioned in the protocol.
  • Drug: Placebo — Placebo will be administered as per the schedule mentioned in the protocol.

Primary Outcomes

  • Percentage of Participants With Confirmed Objective Response (cORR) (Up to approximately 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-04-07
Completion: 2030-02-26
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hoffmann-La Roche
Principal Investigators:
  • Clinical Trials (STUDY_DIRECTOR) - Hoffmann-La Roche
Contact Information
Study Contact:
Reference Study ID Number: CO46274 https://forpatients.roche.com/ No attachments to email below.
888-662-6728
global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Interventions
  • Drug: Inavolisib — Inavolisib will be administered as per the schedule mentioned in the protocol.
  • Drug: Ribociclib — Ribociclib will be administered as per the schedule mentioned in the protocol.
  • Drug: Fulvestrant — Fulvestrant will be administered as per the schedule mentioned in the protocol.
  • Drug: Placebo — Placebo will be administered as per the schedule mentioned in the protocol.
Study Locations (58 sites)
Los Angeles Cancer Network - Anaheim, Anaheim, California 92805 United States
Stanford Cancer Institute, Palo Alto, California 94304 United States
Cancer Specialists of North Florida, Jacksonville, Florida 32256 United States
Avera Cancer Institute - Marshall, Marshall, Minnesota 56258 United States
Avera Cancer Institute - Aberdeen, Aberdeen, South Dakota 57401 United States
Avera Cancer Institute - Mitchell, Mitchell, South Dakota 57301 United States
Avera Cancer Institute - Pierre, SD, Pierre, South Dakota 57501 United States
Avera Cancer Institute, Sioux Falls, South Dakota 57105 United States
AMG Oncology and Hematology Avera Cancer Institute - Yankton, Yankton, South Dakota 57078 United States
Medical College of Wisconsin, Milwaukee, Wisconsin 53226 United States
Eligibility Criteria
Inclusion Criteria: * Women or men with histologically or cytologically confirmed carcinoma of the breast that is locally advanced or metastatic and is not amenable to surgical or radiation therapy with curative intent * Documented estrogen receptor (ER)-positive and/or progesterone receptor (PR)-positive tumor according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines, defined as \>=1% of tumor cells stained positive based on the most recent tumor biopsy and assessed locally (Allison et al. 2020) * Participants must not have received any prior systemic therapy for locally advanced unresectable or metastatic breast cancer (mBC) and must have progressed during adjuvant endocrine-based treatment or within 12 months after completing adjuvant endocrine-based therapy with an aromatase inhibitor or tamoxifen * Confirmed biomarker eligibility as documented through central laboratory testing of a tumor tissue sample documenting both the lack of a phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) mutation and the presence of heterozygous loss of chromosome 8p (i.e., PIK3CAnmd and chr8p loss) * Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) Exclusion Criteria: * Metaplastic breast cancer * Radiotherapy within 2 weeks before randomization * Appropriate for treatment with cytotoxic chemotherapy at time of entry into the study, as per national or local treatment guidelines (e.g., participants with visceral crisis) * Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes * Known and untreated, or active Central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control). Participants with a history of treated CNS metastases are eligible * Any history of leptomeningeal disease or carcinomatous meningitis
Conditions Depression - Major Depressive Disorder, ...
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Depression and anxiety affects levels of function across different levels like work, increasing levels of sick leave and as well as cognitive functioning. In the current study patients at risk of sick leave with depression and anxiety receive metacognitive therapy and work focus in an ordinary outpatient clinic. Impaired cognitive functioning may also be of importance in the return to work process and degree of sick leave. It is important to get a better understanding of how cognitive functioning is related to sick leave and if it predicts return to work, and if cognitive functioning is changed due to psychological treatment.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Primary Outcomes

  • Patient Health Questionnaire-9 (PHQ-9) (Measured at pre-treatment and at therapy completion, an average of 10 weekly sessions, and at 6, 12 months follow-up)
  • Generalized Anxiety Disorder (GAD-7) (Measured at pre-treatment and at therapy completion, an average of 10 weekly sessions, and at 6, 12 months follow-up)
  • Changes in sick leave (Measured at pre-treatment and at therapy completion, an average of 10 weekly sessions, and at 6, 12 months follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-01-01
Completion: 2032-08-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Norwegian University of Science and Technology
Collaborators: Diakonhjemmet Hospital, The Research Council of Norway
Contact Information
Study Contact:
Odin Hjemdal, PhD
+4773597889
odin.hjemdal@ntnu.no
Odin Hjemdal, PhD
+4773597889
odin.hjemdal@ntnu.no
Diakonhjemmet hospital
Interventions
N/A
Study Locations (1 sites)
Diakonhjemmet hospital, Oslo, Norway
Eligibility Criteria
Inclusion Criteria: * diagnosis of depression and/or anxiety, * at risk of sick leave Exclusion Criteria: * personality disorders cluster A or B, * ongoing substance abuse, * symptoms of psychosis, * acute suicidality, * serious somatic disorders
Conditions Breast Cancer, Colorectal Cancer, Ovaria...
Phase NA
Enrollment 98
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A single-center, randomized (1:1) open-label, prospective, stratified study with two parallel arms, designed to evaluate adherence to the adapted physical activity (APA) program for patients participating in an APA program and to compare changes in fatigue at 3 months in patients who have completed adjuvant systemic chemotherapy for cancer and are participating in an APA program.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: APA program — patient will benefit of an activity monitored by a wtach and an APA program during 3 months

Primary Outcomes

  • adherence to the adapted physical activity (APA) program by the percentage of patients who completed 75% of the weekly sessions of the APA program with a heart rate (HR) between 40 and 60% of their reserve HR for 20-40 minutes. (3 months)
  • evolution of fatigue in patients who are participating in an APA program by the difference in Multidimensional Fatigue Inventory (MFI-20) questionnaire scores (20 items) between the first and last visit at 3 months. (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-09-15
Completion: 2030-06-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 98 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Antoine Lacassagne
Collaborators: Centre Hospitalier Universitaire de Nice
Contact Information
Study Contact:
Ludovic EVESQUE, Doctor
+33 492 03 16 22
ludovic.evesque@nice.unicancer.fr
Ludovic EVESQUE, doctor
+33 492 03 16 22
ludovic.evesque@nice.unicancer.fr
Centre Antoine Lacassagne
Ludovic EVESQUE, doctor
Centre Antoine Lacassagne
Interventions
  • Other: APA program — patient will benefit of an activity monitored by a wtach and an APA program during 3 months
Study Locations (1 sites)
Centre Antoine Lacassagne, Nice, 06100 France
Eligibility Criteria
Inclusion Criteria: 1. Patients aged 18 to 75 years old, 2. Histologically proven non-metastatic adenocarcinoma of breast, colorectal, ovarian, pancreatic, biliary, or gastric origin, 3. Adjuvant chemotherapy completed less than 3 months ago (excluding hormone therapy), 4. PS 0 or 1 according to the World Health Organization (WHO) scale, 5. No recurrence since the end of adjuvant chemotherapy, 6. Patient who has voluntarily agreed to participate in the study and sign the written informed consent form, 7. Patient affiliated with a Social Security scheme. Exclusion Criteria: 1. New cancer treatment planned (excluding hormone therapy), 2. Patient who has received adjuvant immunotherapy, 3. Cardiological contraindication to the program 4. Decompensated or unstable chronic conditions 5. Severe malnutrition 6. Rheumatological unfitness as determined by the oncologist, 7. Chronic respiratory failure requiring long-term O2 therapy 8. Diabetes with plantar ulceration 9. Progressive or chronic non-healing bedsore/wound 10. Recent unhealed fracture 11. Patient participating in another interventional clinical study at the time of signing the informed consent form. 12. Vulnerable persons as defined in Articles L1121-5 to -8
Conditions Depression Disorder, Chronic Pain
Phase NA
Enrollment 160
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if active transcranial alternating current stimulation (tACS) and transcranial direct current stimulation (tDCS) can improve pain symptoms in patients with major depressive disorder (MDD) and chronic pain symptoms. It will also explore the neural mechanisms underlying these potential effects. The main questions it aims to answer are: 1. Are there any differences in the overall efficacy among the three intervention groups (tACS, tDCS, and sham)? 2. Is active tACS superior to sham stimulation in reducing pain symptoms in patients with MDD and chronic pain over the 2-week treatment period and at the 6-week follow-up? 3. Is active tACS superior to active tDCS in reducing pain symptoms? 4. Does active tACS, compared to tDCS, demonstrate a more persistent improvement in pain symptoms, as measured at the 6-week follow-up? 5. As an exploratory objective, what neural oscillation entrainment mechanisms underlie the potential analgesic effects of tACS? Researchers will compare three parallel groups: active tACS, active tDCS, and sham stimulation, to evaluate their efficacy. All three groups are randomized and double-blinded. In addition, a separate exploratory open-label cohort of 10 participants will receive the same active tACS intervention while performing a cognitive task. This exploratory arm is designed to investigate the neural oscillation entrainment effects of tACS. Data from this arm will be analyzed separately and are not included in the primary confirmatory analyses. Participants in the main randomized trial will: 1. Receive 40 minutes of stimulation (tACS, tDCS, or sham) once daily, 5 days per week, for 2 weeks (10 sessions total). 2. Complete clinical assessments and cognitive tests at baseline, mid-intervention (week 1), post-intervention (week 2), and at a 6-week follow-up. 3. Undergo resting-state functional MRI (rs-fMRI) and blood sample collection at baseline and post-intervention for exploratory biomarker analyses. Participants in the exploratory open-label arm will: 1. Receive active tACS (1 mA, 10 Hz, 40 minutes) once daily, 5 days per week, for 2 weeks (10 sessions total), while performing a cognitive task during stimulation. 2. Complete resting-state and task-state EEG recordings at the following time points: (1) At baseline (pre-intervention) (2) Immediately before and after the 1st tACS session (3) Immediately before and after the 10th tACS session (4) On the day after completion of all 10 sessions These EEG recordings are designed to assess: (1) the immediate entrainment effects of a single tACS session, (2) the cumulative effects after repeated tACS sessions, and (3) the persistent neural plasticity changes following the full intervention course.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: tDCS — Participants receive active tDCS. The anodal electrode (5 × 5 cm) is placed over the left dorsolateral prefrontal cortex (F3), and the cathodal electrode (5 × 7 cm) is placed over the right dorsolateral prefrontal cortex (F4). A constant current of 2 mA is applied for 40 minutes per session, with a 30-second ramp-up and ramp-down period. The intervention is administered once daily for 2 weeks (total of 10 sessions).
  • Device: alpha-tACS — Participants receive active alpha-tACS. Two electrodes are placed over F3 and F4. A sinusoidal alternating current at 10 Hz frequency (alpha band) is applied 1 mA (zero-to-peak) at the F3 and F4 electrodes. Stimulation duration is 40 minutes per session, including 30-second ramp-up and ramp-down periods. The intervention is administered once daily, 5 days per week, for 2 weeks (total of 10 sessions).
  • Device: Sham — Sham group using the same electrode montage at F3/F4. To maintain blinding, the stimulator delivers current only during the initial 30-second ramp-up period, followed by an immediate ramp-down, and a final 30-second ramp-up at the end of the stimulation session. This mimics the initial sensation of active stimulation without delivering sufficient current to induce neural modulation.

Primary Outcomes

  • Proportion of Participants Achieving MCID on BPI Pain Intensity Subscale (At 1 week (mid-intervention), 2 weeks (end of intervention), and 6 weeks (follow-up) post-baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-11
Completion: 2028-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 160 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai Mental Health Center
Collaborators: Shanghai 10th People's Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine
Contact Information
Study Contact:
Jianhua Chen
(+86) 18017311011
jianhua.chen@smhc.org.cn
jianhua Chen
(+86) 18017311011
jianhua.chen@smhc.org.cn
Shanghai Mental Health Center
haoyun Tang
(+86) 18117197217
tanghy0809@163.com
Shanghai Mental Health Center
Interventions
  • Device: tDCS — Participants receive active tDCS. The anodal electrode (5 × 5 cm) is placed over the left dorsolateral prefrontal cortex (F3), and the cathodal electrode (5 × 7 cm) is placed over the right dorsolateral prefrontal cortex (F4). A constant current of 2 mA is applied for 40 minutes per session, with a 30-second ramp-up and ramp-down period. The intervention is administered once daily for 2 weeks (total of 10 sessions).
  • Device: alpha-tACS — Participants receive active alpha-tACS. Two electrodes are placed over F3 and F4. A sinusoidal alternating current at 10 Hz frequency (alpha band) is applied 1 mA (zero-to-peak) at the F3 and F4 electrodes. Stimulation duration is 40 minutes per session, including 30-second ramp-up and ramp-down periods. The intervention is administered once daily, 5 days per week, for 2 weeks (total of 10 sessions).
  • Device: Sham — Sham group using the same electrode montage at F3/F4. To maintain blinding, the stimulator delivers current only during the initial 30-second ramp-up period, followed by an immediate ramp-down, and a final 30-second ramp-up at the end of the stimulation session. This mimics the initial sensation of active stimulation without delivering sufficient current to induce neural modulation.
Study Locations (2 sites)
Shanghai Mental Health Center, Shanghai, Shanghai Municipality 200030 China
Shanghai Tenth People's Hospital, Shanghai, Shanghai Municipality 200072 China
Eligibility Criteria
Inclusion Criteria: 1. Meets the diagnostic criteria for a depressive episode (DSM-5); 2. HAMD-17 score of ≥8 and ≤23 (mild-to-moderate depressive symptoms) based on the current assessment; 3. 4 or higher on Item 5 of the Brief Pain Inventory (BPI), and persistent pain lasting more than three months; 4. Ages 18-80; 5. Right-handed, with normal hearing, vision, or corrected vision; 6. Have a high school education or higher and be able to understand and complete research-related assessments; 7. Maintain a consistent regimen of analgesic and antidepressant medications and psychotherapy (including dosage and type of medication or treatment method) for four weeks prior to enrollment; 8. The subject (or his or her legal representative, if applicable) signed an informed consent form stating that he or she understood the purpose and procedure of the trial and was willing to participate in it. Exclusion Criteria: 1. Diagnosed according to the DSM-5 as meeting any of the following criteria: ① Major depressive disorder or treatment-resistant depression (HAMD-17 score ≥ 24, and the current episode has lasted ≥ 2 years, or the current episode has been unresponsive to treatment with ≥ 2 antidepressants); ② Schizophrenia spectrum disorder; ③ Bipolar I disorder; ④ Anxiety disorders (including generalized anxiety disorder, panic disorder, social anxiety disorder, etc.); ⑤ Depressive disorder caused by a medical condition. 2. Experiencing malignant pain caused by cancer pain syndrome, visceral pain (such as stomach pain), referred pain (such as back pain caused by pancreatitis), and so on; 3. Patients with severe or unstable physical illnesses, including but not limited to: neurological disorders (such as epilepsy, stroke, migraine, history of cranial surgery, etc.); neurological disorders accompanied by structural brain abnormalities (e.g., traumatic brain injury, recent stroke, brain tumor); cardiovascular diseases (e.g., uncontrolled hypertension, heart failure, arrhythmias, myocardial infarction, etc.); respiratory diseases (e.g., severe sleep apnea syndrome); malignant tumors or immunodeficiency; uncontrolled diabetes (fasting blood glucose \> 12 mmol/L); 4. Excessive alcohol consumption within 30 days prior to the start of the trial, or a history of alcohol or drug dependence within the past 6 months; 5. Women who are pregnant, breastfeeding, or planning to become pregnant within 3 months of the start of the trial; 6. Currently taking medications that affect cortical excitability (e.g., benzodiazepines, antiepileptic drugs); 7. Have undergone neurostimulation therapy within the past 3 months, including electroconvulsive therapy (MECT), repetitive transcranial magnetic stimulation (rTMS), or transcranial electrical stimulation (tES); 8. Suffers from claustrophobia and is unable to undergo an fMRI scan (applies to subjects who require a functional MRI scan); 9. Contraindications to transcranial electrical stimulation (such as intracranial metal implants, pacemakers, cochlear implants, skin abrasions at the stimulation site, or a personal or family history of epilepsy, etc.); 10. Currently participating in another clinical trial, has participated in a clinical trial within the past 90 days, or plans to participate in another clinical trial during the study; 11. Participants with obvious suicidal tendencies, impulsive behavior, or an inability to cooperate with study evaluators; 12. Accompanied by psychotic symptoms; 13. Researchers believe there are other circumstances that make a participant unsuitable for the trial; 14. Patients with severe cognitive impairment (MMSE ≤ 17) were excluded; 15. Participants who are unable to cooperate with the study; 16. Those who voluntarily withdrew midway.
Conditions Postpartum Depression (PPD)
Phase NA
Enrollment 352
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Postpartum depression (PPD) is a common and serious condition affecting 9.5% of women in high-income countries, and around 8% in Denmark. It shares core features with major depression, including low mood, loss of interest, and impaired functioning. Untreated PPD can persist for months, negatively impacting maternal well-being, child development, and family dynamics. In Denmark, systematic screening using the Edinburgh Postnatal Depression Scale (EPDS) is standard practice, but access to PPD treatment varies widely across municipalities. Cognitive behavioral therapy (CBT) is the most effective psychological intervention for perinatal depression, yet limited availability and long wait times create barriers to access to care. Internet-based CBT (iCBT) offers a scalable, cost-effective alternative that can be delivered flexibly at home. Evidence supports the efficacy of self-guided iCBT for depression, though challenges such as high dropout rates have been reported. International trials in Norway, Portugal, Iran, South Korea, and the US have shown promising results for iCBT in perinatal populations. Some recent iCBT based interventions have also incorporated elements of Acceptance and Commitment Therapy (ACT) - which emphasizes psychological flexibility via mindfulness-based acceptance and values-driven action-and have demonstrated efficacy in reducing postpartum depression symptoms. These kinds of interventions (either iCBT or iCBT + ACT) have not yet been tested and evaluated in Denmark. This clinical trial aims to evaluate whether adding an iCBT intervention with elements from ACT (iCARE) to treatment as usual (TAU) is more effective than TAU alone in reducing depressive symptoms in mothers with symptoms of PPD. Moreover, a qualitative process evaluation of the iCARE will explore implementation, acceptability, and mechanisms of impact. Its primary aim is to understand how participants experience the iCARE intervention and TAU, focusing on implementation fidelity, acceptability, and contextual influences. The secondary aim is to explore perceived mechanisms of change (e.g., cognitive, emotional, behavioral) and barriers/facilitators to engagement.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Internet-based therapy (iCARE) and treatment as usual — The iCARE program is a self-guided iCBT intervention that also incorporates selected exercises and approaches from ACT. The iCARE program consists of four core modules and four optional modules. Together, these exercises aim to enhance psychological flexibility, reduce negative thinking, and promote well-being in daily life. The core modules focus on self-care and mindfulness (Module 1), identifying and reframing unrealistic expectations with self-compassion (Module 2), increasing positive experiences and countering self-critical thoughts (Module 3), and recognizing and challenging thinking traps (Module 4). The additional optional modules provide strategies for practicing being present, communicating needs and asking for support, bonding with the baby, and coping with scary thoughts.
  • Other: Treatment as usual (TAU) — In Denmark, there is large variation in the available prevention and treatment municipalities offers for women experiencing symptoms of PPD. Some municipalities offer specialized psychological support and support groups, while others provide only basic follow-up by health nurses. Women can also be referred to their general practitioner, who can provide free ongoing follow-up and prescribe antidepressant medication if needed. Alternatively, it is possible to be referred to a privately practicing psychologist, usually with some out-of-pocket cost.

Primary Outcomes

  • Symptoms of postpartum depression (Baseline At 2 months (primary endpoint) At 6 months (secondary endpoint))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-01
Completion: 2028-08-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 352 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Southern Denmark
Collaborators: University of Copenhagen, Odense University Hospital
Contact Information
Study Contact:
Trine Munk-Olsen, PhD
+4524466297
tmun@sdu.dk
Trine Munk-Olsen, PhD
+4524466297
tmun@sdu.dk
Research Unit of Child and Adolescent Psychiatry, Department of Clinical Research, University of Southern Denmark
Interventions
  • Behavioral: Internet-based therapy (iCARE) and treatment as usual — The iCARE program is a self-guided iCBT intervention that also incorporates selected exercises and approaches from ACT. The iCARE program consists of four core modules and four optional modules. Together, these exercises aim to enhance psychological flexibility, reduce negative thinking, and promote well-being in daily life. The core modules focus on self-care and mindfulness (Module 1), identifying and reframing unrealistic expectations with self-compassion (Module 2), increasing positive experiences and countering self-critical thoughts (Module 3), and recognizing and challenging thinking traps (Module 4). The additional optional modules provide strategies for practicing being present, communicating needs and asking for support, bonding with the baby, and coping with scary thoughts.
  • Other: Treatment as usual (TAU) — In Denmark, there is large variation in the available prevention and treatment municipalities offers for women experiencing symptoms of PPD. Some municipalities offer specialized psychological support and support groups, while others provide only basic follow-up by health nurses. Women can also be referred to their general practitioner, who can provide free ongoing follow-up and prescribe antidepressant medication if needed. Alternatively, it is possible to be referred to a privately practicing psychologist, usually with some out-of-pocket cost.
Study Locations (1 sites)
Research Unit of Child and Adolescent Psychiatry, Department of Clinical Research, University of Southern Denmark, Odense, 5250 Denmark
Eligibility Criteria
Inclusion Criteria: * Given birth within 6 months * Edinburgh Postnatal Depression Scale (EPDS) score above 7 * ≥age 18 * Access to the internet Exclusion Criteria: * Do not understand Danish language, * Substance abuse or dependence * Alcohol abuse, defined by a weekly consumption of alcohol exceeding 10 units * A diagnosis of schizophrenia, other psychotic disorders or in immediate need of psychiatric treatment.
Conditions Geriatric Assessment, Adjuvant Drug Ther...
Phase Not Applicable
Enrollment 200
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Older breast cancer patients should not be categorically excluded from adjuvant therapies, including the recommended CDK4/6 inhibitors (CDK4/6i) administered in combination with endocrine therapy. Nevertheless, this population frequently presents with comorbidities that may increase susceptibility to treatment-related toxicities, including impacts on quality of life, which must be carefully considered when selecting therapeutic regimens. Given the limited representation of older patients in the clinical trials behind the recommendations for adjuvant CDK4/6i therapy, coupled with the uncertain magnitude of clinical benefit and the reported rates of toxicity and treatment discontinuation, it is essential to critically evaluate both efficacy and safety in this specific patient subgroup. National and international guidelines recommend the integration of geriatric assessments into routine clinical practice to facilitate individualized treatment decisions; however, such assessments are not yet widely implemented in many oncology departments and are not routinely in use to guide adjuvant CDK4/6i therapy. This study aims to investigate the implementation of geriatric assessments in older breast cancer patients (≥70 years) and to examine multiple dimensions of CDK4/6i treatment in this cohort, including short- and medium-term effects on quality of life, dose intensity, and clinical outcomes. By doing so, the investigators seek to more accurately delineate the benefits and risks of adjuvant CDK4/6i therapy in this specific patient population.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Frailty as assessed by Geriatric 8 (G8) (Baseline)
  • Frailty as assessed by Vulnerable Elders Survey (VES-13) (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-04-01
Completion: 2039-08-01
Eligibility
Age: 70 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Region Jönköping County
Collaborators: Region Örebro County, Region Östergötland, Region Gävleborg, Västra Götalandsregionen, Linkoeping University, Örebro University, Sweden, Kalmar County Hospital
Principal Investigators:
  • Christine Lundgren, MD (STUDY_CHAIR) - Department of Oncology, Jönköping, Region Jönköping County, Jönköping; Sweden,
Contact Information
Study Contact:
Christine Lundgren, MD
+46102422907
christine.lundgren@rjl.se
Ilke Cikman, MD
ilke.cikman@regiongavleborg.se
Department of Oncology
Christine Lundgren, MD
+46102422907
christine.lundgren@rjl.se
Department of Oncology
Interventions
N/A
Study Locations (5 sites)
Department of Oncology, Gävle, Sweden
Department of Oncology, Jönköping, 55312 Sweden
Department of Oncology, Kalmar, Sweden
Department of Oncology, Linköping, Sweden
Department of Oncology, Örebro, Sweden
Eligibility Criteria
Inclusion Criteria: * ≥70 years old * Female/male * Completed surgery (primary or after neoadjuvant therapy) * Starting adjuvant CDK4/6i and endocrine therapy * Cognitive performance to be able answer questionaries * No language difficulties Exclusion Criteria: * Impaired cognitive function not able to understand the study intention or perform questionaries * Declining adjuvant CDK4/6i

TIPS With or Without BCAA

NCT07281846
Recruiting
Conditions BCAA, Cirrhosis, Portal Hypertension Rel...
Phase NA
Enrollment 164
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Cirrhosis is a major global cause of morbidity and mortality in chronic liver disease patients, accounting for 2.4% of global deaths in 2019. A 1990-2017 Global Burden of Disease study showed rising cirrhosis-related deaths, bringing heavy health and economic burdens. It often leads to portal hypertension and subsequent complications like ascites, gastroesophageal variceal bleeding (20% 6-week mortality), and hepatic encephalopathy (HE). Transjugular intrahepatic portosystemic shunt (TIPS) is an important treatment for variceal bleeding and refractory ascites per guidelines from EASL, AASLD, and the Chinese Medical Association. Malnutrition affects 20% of compensated and over 50% of decompensated cirrhotic patients; sarcopenia (severe malnutrition) is linked to higher cirrhosis-related complications, impaired quality of life, survival, and poor prognosis in TIPS-treated patients. Thus, concurrent sarcopenia intervention during TIPS may improve outcomes. Baveno VII, EASL, and AASLD guidelines recommend branched-chain amino acid (BCAA) and leucine-rich supplements for decompensated cirrhosis to ensure adequate nitrogen intake. RCT evidence shows BCAAs improve skeletal muscle index (SMI) in cirrhotic patients with sarcopenia and reduce HE risk, but evidence for TIPS-treated patients is lacking. This study aims to compare muscle mass changes and clinical prognosis between TIPS patients with sarcopenia, portal hypertension, and variceal bleeding who receive TIPS with or without BCAA supplements.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: The BCAA Group (experimental group) takes oral branched-chain amino acid (BCAA) supplements for 3 months starting after TIPS. — This prospective randomized controlled trial (RCT) aims to compare changes in muscle mass and clinical outcomes between sarcopenic cirrhotic patients with portal hypertension and variceal bleeding who undergo transjugular intrahepatic portosystemic shunt (TIPS) plus branched-chain amino acid (BCAA) supplementation versus TIPS plus placebo. Eligible patients are aged 18-75 years, with cirrhosis, sarcopenia (defined by EASL guidelines: L3 skeletal muscle index \[L3-SMI\] \<50 cm²/m² for males, \<39 cm²/m² for females, measured via preoperative abdominal CT), and TIPS eligibility due to variceal bleeding or refractory ascites; exclusions include malignancies, severe cardiopulmonary insufficiency, Child-Pugh score \>13, recurrent hepatic encephalopathy (HE), and prior use of nutrition supplements within 3 months. TIPS is standardized with 8mm covered Viatorr stents, intraoperative variceal embolization if needed, and a postoperative portal pressure gradient (PPG) target of \<12 mmHg or ≥50% base
  • Dietary Supplement: The Placebo Group (control group) takes oral placebo for 3 months postoperatively-prepared by an independent third party, the placebo is identical to BCAA supplements in appearance, odor, and packagin — The Placebo Group (control group) takes oral placebo for 3 months postoperatively-prepared by an independent third party, the placebo is identical to BCAA supplements in appearance, odor, and packaging to maintain blinding.

Primary Outcomes

  • Differences in the sarcopenia reversal rate between the two groups (BCAA and Non-BCAA) (1 year)
  • Differences in Short Physical Performance Battery (SPPB) scores between the two groups (BCAA and Non-BCAA) (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-15
Completion: 2027-11-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 164 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators: The First Affiliated Hospital of Zhengzhou University, The First Affiliated Hospital of Henan University of Science and Technology
Contact Information
Study Contact:
Yaowei Bai
+8618627162379
baiyaowei918@163.com
Yaowei Bai
+8618627162379
baiyaowei918@163.com
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
baiyaowei918@163.com
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Interventions
  • Dietary Supplement: The BCAA Group (experimental group) takes oral branched-chain amino acid (BCAA) supplements for 3 months starting after TIPS. — This prospective randomized controlled trial (RCT) aims to compare changes in muscle mass and clinical outcomes between sarcopenic cirrhotic patients with portal hypertension and variceal bleeding who undergo transjugular intrahepatic portosystemic shunt (TIPS) plus branched-chain amino acid (BCAA) supplementation versus TIPS plus placebo. Eligible patients are aged 18-75 years, with cirrhosis, sarcopenia (defined by EASL guidelines: L3 skeletal muscle index \[L3-SMI\] \<50 cm²/m² for males, \<39 cm²/m² for females, measured via preoperative abdominal CT), and TIPS eligibility due to variceal bleeding or refractory ascites; exclusions include malignancies, severe cardiopulmonary insufficiency, Child-Pugh score \>13, recurrent hepatic encephalopathy (HE), and prior use of nutrition supplements within 3 months. TIPS is standardized with 8mm covered Viatorr stents, intraoperative variceal embolization if needed, and a postoperative portal pressure gradient (PPG) target of \<12 mmHg or ≥50% base
  • Dietary Supplement: The Placebo Group (control group) takes oral placebo for 3 months postoperatively-prepared by an independent third party, the placebo is identical to BCAA supplements in appearance, odor, and packagin — The Placebo Group (control group) takes oral placebo for 3 months postoperatively-prepared by an independent third party, the placebo is identical to BCAA supplements in appearance, odor, and packaging to maintain blinding.
Study Locations (1 sites)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Eligibility Criteria
Inclusion Criteria: 1. Age between 18 and 80 years old; 2. Diagnosed with cirrhosis complicated by sarcopenia; 3. Patients admitted due to variceal bleeding or refractory ascites who meet the indications for transjugular intrahepatic portosystemic shunt (TIPS). Exclusion Criteria: 1. Hepatocellular carcinoma and/or other malignant tumors; 2. Severe cardiopulmonary insufficiency; 3. Child-Pugh score \> 13 points; 4. Spontaneous recurrent hepatic encephalopathy (HE); 5. Large spontaneous portosystemic shunt; 6. Sepsis; spontaneous bacterial peritonitis (SBP); 7. Allergy to any component of the study nutritional supplement; 8. High-energy and high-protein diet or use of calcium supplements, vitamin D supplements, or protein/amino acid supplements within 3 months prior to the study.